Reviparin sodium

	WikiDoc Resources for Reviparin sodium
Articles
Most recent articles on Reviparin sodium Most cited articles on Reviparin sodium Review articles on Reviparin sodium Articles on Reviparin sodium in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Reviparin sodium Images of Reviparin sodium Photos of Reviparin sodium Podcasts & MP3s on Reviparin sodium Videos on Reviparin sodium
Evidence Based Medicine
Cochrane Collaboration on Reviparin sodium Bandolier on Reviparin sodium TRIP on Reviparin sodium
Clinical Trials
Ongoing Trials on Reviparin sodium at Clinical Trials.gov Trial results on Reviparin sodium Clinical Trials on Reviparin sodium at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Reviparin sodium NICE Guidance on Reviparin sodium NHS PRODIGY Guidance FDA on Reviparin sodium CDC on Reviparin sodium
Books
Books on Reviparin sodium
News
Reviparin sodium in the news Be alerted to news on Reviparin sodium News trends on Reviparin sodium
Commentary
Blogs on Reviparin sodium
Definitions
Definitions of Reviparin sodium
Patient Resources / Community
Patient resources on Reviparin sodium Discussion groups on Reviparin sodium Patient Handouts on Reviparin sodium Directions to Hospitals Treating Reviparin sodium Risk calculators and risk factors for Reviparin sodium
Healthcare Provider Resources
Symptoms of Reviparin sodium Causes & Risk Factors for Reviparin sodium Diagnostic studies for Reviparin sodium Treatment of Reviparin sodium
Continuing Medical Education (CME)
CME Programs on Reviparin sodium
International
Reviparin sodium en Espanol Reviparin sodium en Francais
Business
Reviparin sodium in the Marketplace Patents on Reviparin sodium
Experimental / Informatics
List of terms related to Reviparin sodium

Reviparin sodium
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AB08 (WHO) ;
Identifiers
CAS Number	9041-08-1 ;
ChemSpider	NA ;
KEGG	D06398 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Pharmacodynamic

Reviparin is a low molecular weight heparin (LMWH) obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

Indications

Prophylaxis of deep vein thrombosis (DVT)
Prophylaxis of perioperative thromboembolism^[1]^[2]
Treatment of DVT with or without pulmonary embolism (PE)^[3]
Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)^[4]^[5]

References

↑ Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. PMID 8822126. |access-date= requires |url= (help)
↑ Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720. |access-date= requires |url= (help)
↑ Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830. |access-date= requires |url= (help)
↑ Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331. |access-date= requires |url= (help)
↑ Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMID 8917255. Retrieved 2014-09-18.

External links

reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
Yusuf S, Mehta SR, Xie C; et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.

[pmid8822126-1] Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. PMID 8822126. |access-date= requires |url= (help)

[pmid10549720-2] Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720. |access-date= requires |url= (help)

[pmid15887830-3] Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830. |access-date= requires |url= (help)

[pmid8180331-4] Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331. |access-date= requires |url= (help)

[pmid8917255-5] Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMID 8917255. Retrieved 2014-09-18.

[1]

[2]

[3]

[4]

[5]